≥70岁COVID-19患者中的无创通气:一项前瞻性多中心队列研究
这是COVIP研究的一项子研究,为国际前瞻性观察性研究,纳入15个欧洲国家156个ICU中年龄≥70岁、确诊COVID-19并接受ICU治疗的患者,招募时间为2020年3月至2021年4月,主要终点为30天死亡率。队列共3074例患者,平均年龄75.7岁(SD 4.6),男性2197/3074(71.4%)。无创通气使用频率为25.7%,各国之间从1.1%到62.0%不等。无创通气失败(定义为需要气管插管或ICU入住后30天内死亡)发生在470/629(74.7%)的患者中。SOFA评分较高(OR 3.73,95% CI 2.36-5.90)和入院时临床衰弱量表评分较高(OR 1.46,95% CI 1.06-2.00)与无创通气失败风险增加相关。初始接受无创通气的患者(n=630)比初始有创机械通气组(n=1876)少存活1.36天(95% CI -2.27至-0.46天)。
要点
- 在≥70岁COVID-19 ICU患者中,无创通气失败(需气管插管或ICU入住后30天内死亡)发生在470/629(74.7%)的患者中。
- SOFA评分较高与无创通气失败风险增加相关(OR 3.73,95% CI 2.36-5.90)。
- 入院时临床衰弱量表评分较高与无创通气失败风险增加相关(OR 1.46,95% CI 1.06-2.00)。
- 初始接受无创通气的患者(n=630)比初始有创机械通气组(n=1876)少存活1.36天(95% CI -2.27至-0.46天)。
- 无创通气使用频率在欧洲各国之间差异很大,从1.1%到62.0%不等。
适用人群与场景
- 年龄≥70岁、确诊COVID-19并接受ICU治疗的患者,来自15个欧洲国家的156个ICU。
研究设计与关键结果
- 研究类型为国际前瞻性观察性研究(COVIP研究子研究),纳入156个ICU、15个欧洲国家的3074例患者,招募时间为2020年3月至2021年4月。
- 队列平均年龄75.7岁(SD 4.6),男性2197/3074(71.4%)。
- 无创通气使用频率为25.7%,各国之间从1.1%到62.0%不等。
- 主要终点为30天死亡率;无创通气失败定义为需要气管插管或ICU入住后30天内死亡,发生在470/629(74.7%)的患者中。
- SOFA评分较高与无创通气失败风险增加相关(OR 3.73,95% CI 2.36-5.90)。
- 入院时临床衰弱量表评分较高与无创通气失败风险增加相关(OR 1.46,95% CI 1.06-2.00)。
- 初始接受无创通气的患者(n=630)比初始有创机械通气组(n=1876)少存活1.36天(95% CI -2.27至-0.46天)。
证据类型、等级与局限
- 证据类型:国际前瞻性观察性队列研究(COVIP研究子研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在≥70岁COVID-19 ICU患者中,初始有创机械通气与比初始无创通气更好的结局相关(存活天数更多)。
- SOFA评分较高和临床衰弱量表评分较高的患者无创通气失败风险增加,应考虑更早评估插管需求。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Noninvasive ventilation (NIV) is a promising alternative to invasive mechanical ventilation (IMV) with a particular importance amidst the shortage of intensive care unit (ICU) beds during the COVID-19 pandemic. We aimed to evaluate the use of NIV in Europe and factors associated with outcomes of patients treated with NIV.
METHODS: This is a substudy of COVIP study-an international prospective observational study enrolling patients aged ≥ 70 years with confirmed COVID-19 treated in ICU. We enrolled patients in 156 ICUs across 15 European countries between March 2020 and April 2021.The primary endpoint was 30-day mortality.
RESULTS: Cohort included 3074 patients, most of whom were male (2197/3074, 71.4%) at the mean age of 75.7 years (SD 4.6). NIV frequency was 25.7% and varied from 1.1 to 62.0% between participating countries. Primary NIV failure, defined as need for endotracheal intubation or death within 30 days since ICU admission, occurred in 470/629 (74.7%) of patients. Factors associated with increased NIV failure risk were higher Sequential Organ Failure Assessment (SOFA) score (OR 3.73, 95% CI 2.36-5.90) and Clinical Frailty Scale (CFS) on admission (OR 1.46, 95% CI 1.06-2.00). Patients initially treated with NIV (n = 630) lived for 1.36 fewer days (95% CI - 2.27 to - 0.46 days) compared to primary IMV group (n = 1876).
CONCLUSIONS: Frequency of NIV use varies across European countries. Higher severity of illness and more severe frailty were associated with a risk of NIV failure among critically ill older adults with COVID-19. Primary IMV was associated with better outcomes than primary NIV. Clinical Trial Registration NCT04321265 , registered 19 March 2020, https://clinicaltrials.gov .
参考来源
- Polok K, Fronczek J, Artigas A, et al. Noninvasive ventilation in COVID-19 patients aged ≥ 70 years-a prospective multicentre cohort study. Crit Care. 2022. PMID: 35869557. doi:10.1186/s13054-022-04082-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。